Is physical exercise a multiple sclerosis disease modifying treatment?

References

• Mayr WT, Pittock SJ, McClelland RL, et al. Incidence and prevalence of multiple sclerosis in Olmsted County, Minnesota, 1985–2000. Neurology. 2003;61:1373–1377.
   PubMed Web of Science ®Google Scholar
• Page WF, Kurtzke JF, Murphy FM, et al. Epidemiology of multiple sclerosis in U.S. veterans: V. Ancestry and the risk of multiple sclerosis. Ann Neurol. 1993;33:632–639.
   PubMed Web of Science ®Google Scholar
• National Multiple Sclerosis Society. Multiple sclerosis information sourcebook. New York (NY): Information Resource Center and Library of the National Multiple Sclerosis Society; 2005.
   Google Scholar
• Benito-León J. Multiple sclerosis: is prevalence rising and if so why? Neuroepidemiology. 2011;37:236–237.
   PubMed Web of Science ®Google Scholar
• Hemmer B, Nessler S, Zhou D, et al. Immunopathogenesis and immunotherapy of multiple sclerosis. Nat Clin Pract Neurol. 2006;2:201–211.
   PubMedGoogle Scholar
• Trapp BD, Nave K-A. Multiple sclerosis: an immune or neurodegenerative disorder? Annu Rev Neurosci. 2008;31:247–269.
   PubMed Web of Science ®Google Scholar
• Bjartmar C, Trapp BD. Axonal and neuronal degeneration in multiple sclerosis: mechanisms and functional consequences. Curr Opin Neurol. 2001;14:271–278.
   PubMed Web of Science ®Google Scholar
• Samkoff LM, Goodman AD. Symptomatic management in multiple sclerosis. Neurol Clin. 2011;29:449–463.
   PubMed Web of Science ®Google Scholar
• Katrych O, Simone TM, Azad S, et al. Disease-modifying agents in the treatment of multiple sclerosis: a review of long-term outcomes. CNS Neurol Disord Drug Targets. 2009;8:512–519.
   PubMed Web of Science ®Google Scholar
• Filippini G, Munari L, Incorvaia B, et al. Interferons in relapsing remitting multiple sclerosis: a systematic review. Lancet. 2003;361:545–552.
   PubMed Web of Science ®Google Scholar
• Confavreux C, Vukusic S. The natural history of multiple sclerosis. Rev Prat. 2006;56:1313–1320.
   PubMedGoogle Scholar
• Confavreux C, Vukusic S, Adeleine P. Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. Brain. 2003;126:770–782.
   PubMed Web of Science ®Google Scholar
• Kawalec P, Mikrut A, Wiśniewska N, et al. The effectiveness of dimethyl fumarate monotherapy in the treatment of relapsing-remitting multiple sclerosis: a systematic review and meta-analysis. Curr Neuropharmacol. 2014;12:256–268.
   PubMed Web of Science ®Google Scholar
• Dalgas U, Stenager E. Progressive resistance therapy is not the best way to rehabilitate deficits due to multiple sclerosis: no. Mult Scler J. 2014;20:141–142.
   PubMed Web of Science ®Google Scholar
• Motl RW. Benefits, safety, and prescription of exercise in persons with multiple sclerosis. Expert Rev Neurother. 2014;14:1429–1436.
   PubMed Web of Science ®Google Scholar
• D’hooghe MB, Nagels G, Bissay V, et al. Modifiable factors influencing relapses and disability in multiple sclerosis. Mult Scler. 2010;16:773–785.
   PubMed Web of Science ®Google Scholar
• Dalgas U, Stenager E. Exercise and disease progression in multiple sclerosis: can exercise slow down the progression of multiple sclerosis? Ther Adv Neurol Disord. 2012;5:81–95.
   PubMed Web of Science ®Google Scholar
• Motl RW, Sandroff BM. Benefits of exercise training in multiple sclerosis. Curr Neurol Neurosci Rep. 2015;15:62.
   PubMed Web of Science ®Google Scholar
• Latimer-Cheung AE, Pilutti LA, Hicks AL, et al. Effects of exercise training on fitness, mobility, fatigue, and health-related quality of life among adults with multiple sclerosis: a systematic review to inform guideline development. Arch Phys Med Rehabil. 2013;94:1800–1828.
   PubMed Web of Science ®Google Scholar
• Hyland M, Rudick RA. Challenges to clinical trials in multiple sclerosis: outcome measures in the era of disease-modifying drugs. Curr Opin Neurol. 2011;24:255–261.
   PubMed Web of Science ®Google Scholar
• Goldman MD, Motl RW, Rudick RA. Possible clinical outcome measures for clinical trials in patients with multiple sclerosis. Ther Adv Neurol Disord. 2010;3:229–239.
   PubMedGoogle Scholar
• Berkovich R. Treatment of acute relapses in multiple sclerosis. Neurother. 2013;10:97–105.
   PubMed Web of Science ®Google Scholar
• Goodin DS, Frohman EM, Garmany GP, et al. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology. 2002;58:169–178.
   PubMed Web of Science ®Google Scholar
• Weinshenker BG. Epidemiology of multiple sclerosis. Neurol Clin. 1996;14:291–308.
   PubMed Web of Science ®Google Scholar
• Amato MP, Ponziani G, Bartolozzi ML, et al. A prospective study on the natural history of multiple sclerosis: clues to the conduct and interpretation of clinical trials. J Neurol Sci. 1999;168:96–106.
   PubMed Web of Science ®Google Scholar
• Kappos L, Moeri D, Radue EW, et al. Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis. Gadolinium MRI Meta-analysis Group. Lancet. 1999;353:964–969.
   PubMed Web of Science ®Google Scholar
• Filippi M, Agosta F. Imaging biomarkers in multiple sclerosis. J Magn Reson Imaging. 2010;31:770–788.
   PubMed Web of Science ®Google Scholar
• Healy BC, Ikle D, Macklin EA, et al. Optimal design and analysis of phase I/II clinical trials in multiple sclerosis with gadolinium-enhanced lesions as the endpoint. Mult Scler. 2010;16:840–847.
   PubMed Web of Science ®Google Scholar
• Tremlett H, Yousefi M, Devonshire V, et al. Impact of multiple sclerosis relapses on progression diminishes with time. Neurology. 2009;73:1616–1623.
   PubMed Web of Science ®Google Scholar
• Kurtzke JF. On the origin of EDSS. Mult Scler Relat Disord. 2015;4:95–103.
   PubMed Web of Science ®Google Scholar
• Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33:1444–1452.
   PubMed Web of Science ®Google Scholar
• Learmonth YC, Motl RW, Sandroff BM, et al. Validation of patient determined disease steps (PDDS) scale scores in persons with multiple sclerosis. BMC Neurol. 2013;13:37.
   PubMed Web of Science ®Google Scholar
• Filippini G, Del Giovane C, Vacchi L, et al. Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis. Cochrane Database Syst Rev. 2013;6:CD008933.
   PubMed Web of Science ®Google Scholar
• Kalincik T, Cutter G, Spelman T, et al. Defining reliable disability outcomes in multiple sclerosis. Brain. 2015;138:3287–3298.
   PubMed Web of Science ®Google Scholar
• Amato MP, Fratiglioni L, Groppi C, et al. Interrater reliability in assessing functional systems and disability on the Kurtzke scale in multiple sclerosis. Arch Neurol. 1988;45:746–748.
   PubMed Web of Science ®Google Scholar
• Noseworthy JH, Vandervoort MK, Wong CJ, et al. Interrater variability with the Expanded Disability Status Scale (EDSS) and Functional Systems (FS) in a multiple sclerosis clinical trial. The Canadian Cooperation MS Study Group. Neurology. 1990;40:971–975.
   PubMed Web of Science ®Google Scholar
• Francis DA, Bain P, Swan AV, et al. An assessment of disability rating scales used in multiple sclerosis. Arch Neurol. 1991;48:299–301.
   PubMed Web of Science ®Google Scholar
• Traboulsee A, Zhao G, Li DKB. Neuroimaging in multiple sclerosis. Neurol Clin. 2005;23:131–148.
   PubMed Web of Science ®Google Scholar
• Daumer M, Neuhaus A, Morrissey S, et al. MRI as an outcome in multiple sclerosis clinical trials. Neurology. 2009;72:705–711.
   PubMed Web of Science ®Google Scholar
• Rudick RA, Cutter G. MRI lesions: a surrogate for relapses in multiple sclerosis? Lancet Neurol. 2013;12:628–630.
   PubMed Web of Science ®Google Scholar
• Sormani MP, Bruzzi P. MRI lesions as a surrogate for relapses in multiple sclerosis: a meta-analysis of randomised trials. Lancet Neurol. 2013;12:669–676.
   PubMed Web of Science ®Google Scholar
• Fisher E, Lee J-C, Nakamura K, et al. Gray matter atrophy in multiple sclerosis: a longitudinal study. Ann Neurol. 2008;64:255–265.
   PubMed Web of Science ®Google Scholar
• Fisher E, Rudick RA, Cutter G, et al. Relationship between brain atrophy and disability: an 8-year follow-up study of multiple sclerosis patients. Mult Scler. 2000;6:373–377.
   PubMed Web of Science ®Google Scholar
• Lavorgna L, Bonavita S, Ippolito D, et al. Clinical and magnetic resonance imaging predictors of disease progression in multiple sclerosis: a nine-year follow-up study. Mult Scler J. 2013;20:220–226.
   PubMed Web of Science ®Google Scholar
• Batista S, Zivadinov R, Hoogs M, et al. Basal ganglia, thalamus and neocortical atrophy predicting slowed cognitive processing in multiple sclerosis. J Neurol. 2012;259:139–146.
   PubMed Web of Science ®Google Scholar
• Maghzi A-H, Revirajan N, Julian LJ, et al. Magnetic resonance imaging correlates of clinical outcomes in early multiple sclerosis. Mult Scler Relat Disord. 2014;3:720–727.
   PubMed Web of Science ®Google Scholar
• Bakshi R, Neema M, Healy BC, et al. Predicting clinical progression in multiple sclerosis with the magnetic resonance disease severity scale. Arch Neurol. 2008;65:1449–1453.
   PubMedGoogle Scholar
• Sormani MP, Rovaris M, Comi G, et al. A composite score to predict short-term disease activity in patients with relapsing-remitting MS. Neurology. 2007;69:1230–1235.
   PubMed Web of Science ®Google Scholar
• Cutter GR, Baier ML, Rudick RA, et al. Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain. 1999;122:871–882.
   PubMed Web of Science ®Google Scholar
• Rudick R, Antel J, Confavreux C, et al. Recommendations from the national multiple sclerosis society clinical outcomes assessment task force. Ann Neurol. 1997;42:379–382.
   PubMed Web of Science ®Google Scholar
• Fisher JS, Jak AJ, Knicker JE, et al. Multiple sclerosis functional composite (MSFC): administration and scoring manual. New York (NY): National Multiple Sclerosis Society; 2001.
   Google Scholar
• Lowe MJ, Horenstein C, Hirsch JG, et al. Functional pathway-defined MRI diffusion measures reveal increased transverse diffusivity of water in multiple sclerosis. NeuroImage. 2006;32:1127–1133.
   PubMed Web of Science ®Google Scholar
• Kalkers NF, De Groot V, Lazeron RH, et al. MS functional composite: relation to disease phenotype and disability strata. Neurology. 2000;54:1233–1239.
   PubMed Web of Science ®Google Scholar
• Rudick RA, Cutter G, Baier M, et al. Use of the multiple sclerosis functional composite to predict disability in relapsing MS. Neurology. 2001;56:1324–1330.
   PubMed Web of Science ®Google Scholar
• Fox RJ, Lee JC, Rudick RA. Optimal reference population for the multiple sclerosis functional composite. Mult Scler. 2007;13:909–914.
   PubMed Web of Science ®Google Scholar
• Larocca NG. Impact of walking impairment in multiple sclerosis: perspectives of patients and care partners. The Patient. 2011;4:189–201.
   PubMedGoogle Scholar
• Heesen C, Böhm J, Reich C, et al. Patient perception of bodily functions in multiple sclerosis: gait and visual function are the most valuable. Mult Scler. 2008;14:988–991.
   PubMed Web of Science ®Google Scholar
• Pearson O, Busse M, Van Deursen R, et al. Quantification of walking mobility in neurological disorders. Quarterly J Med. 2004;97:467–475.
   Google Scholar
• Kieseier BC, Pozzilli C. Assessing walking disability in multiple sclerosis. Mult Scler. 2012;18:914–924.
   PubMed Web of Science ®Google Scholar
• Bethoux F, Bennett S. Evaluating walking in patients with multiple sclerosis: which assessment tools are useful in clinical practice? Int J MS Care. 2011;13:4–14.
   PubMedGoogle Scholar
• Schwid SR, Goodman AD, McDermott MP, et al. Quantitative functional measures in MS: what is a reliable change? Neurology. 2002;58:1294–1296.
   PubMed Web of Science ®Google Scholar
• Nilsagard Y, Lundholm C, Gunnarsson L-G, et al. Clinical relevance using timed walk tests and “timed up and go” testing in persons with multiple sclerosis. Physiother Res Int. 2007;12:105–114.
   PubMedGoogle Scholar
• Cohen JA, Krishnan AV, Goodman AD, et al. The clinical meaning of walking speed as measured by the timed 25-foot walk in patients with multiple sclerosis. JAMA Neurol. 2014;71:1386–1393.
   PubMed Web of Science ®Google Scholar
• Goldman MD, Motl RW, Scagnelli J, et al. Clinically meaningful performance benchmarks in MS: timed 25-foot walk and the real world. Neurology. 2013;81:1856–1863.
   PubMed Web of Science ®Google Scholar
• Schwid SR, Goodman AD, Apatoff BR, et al. Are quantitative functional measures more sensitive to worsening MS than traditional measures? Neurology. 2000;55:1901–1903.
   PubMed Web of Science ®Google Scholar
• Goldman MD, Marrie RA, Cohen JA. Evaluation of the six-minute walk in multiple sclerosis subjects and healthy controls. Mult Scler. 2008;14:383–390.
   PubMed Web of Science ®Google Scholar
• Learmonth YC, Dlugonski D, Pilutti LA, et al. The reliability, precision and clinically meaningful change of walking assessments in multiple sclerosis. Mult Scler. 2013;19:1784–1791.
   PubMed Web of Science ®Google Scholar
• Cavanaugh JT, Gappmaier VO, Dibble LE, et al. Ambulatory activity in individuals with multiple sclerosis. J Neurol Phys Ther. 2011;35:26–33.
   PubMed Web of Science ®Google Scholar
• Gijbels D, Alders G, Van Hoof E, et al. Predicting habitual walking performance in multiple sclerosis: relevance of capacity and self-report measures. Mult Scler. 2010;16:618–626.
   PubMed Web of Science ®Google Scholar
• Motl RW, Dlugonski D, Suh Y, et al. Accelerometry and its association with objective markers of walking limitations in ambulatory adults with multiple sclerosis. Arch Phys Med Rehabil. 2010;91:1942–1947.
   PubMed Web of Science ®Google Scholar
• Tallner A, Waschbisch A, Wenny I, et al. Multiple sclerosis relapses are not associated with exercise. Mult Scler. 2012;18:232–235.
   PubMed Web of Science ®Google Scholar
• Pilutti LA, Platta ME, Motl RW, et al. The safety of exercise training in multiple sclerosis: a systematic review. J Neurol Sci. 2014;343:3–7.
   PubMed Web of Science ®Google Scholar
• Snook EM, Motl RW. Effect of exercise training on walking mobility in multiple sclerosis: a meta-analysis. Neurorehabil Neural Repair. 2009;23:108–116.
   PubMed Web of Science ®Google Scholar
• Motl RW, Dlugonski D, Pilutti L, et al. Premorbid physical activity predicts disability progression in relapsing-remitting multiple sclerosis. J Neurol Sci. 2012;323:123–127.
   PubMed Web of Science ®Google Scholar
• Motl RW, McAuley E. Association between change in physical activity and short-term disability progression in multiple sclerosis. J Rehabil Med. 2011;43:305–310.
   PubMed Web of Science ®Google Scholar
• Prakash RS, Snook EM, Motl RW, et al. Aerobic fitness is associated with gray matter volume and white matter integrity in multiple sclerosis. Brain Res. 2010;1341:41–51.
   PubMed Web of Science ®Google Scholar
• Grover SA, Aubert-Broche B, Fetco D, et al. Lower physical activity is associated with higher disease burden in pediatric multiple sclerosis. Neurology. 2015;85:1663–1669.
   PubMed Web of Science ®Google Scholar
• Romberg A, Virtanen A, Ruutiainen J. Long-term exercise improves functional impairment but not quality of life in multiple sclerosis. J Neurol. 2005;252:839–845.
   PubMed Web of Science ®Google Scholar
• Pearson M, Dieberg G, Smart N. Exercise as a therapy for improvement of walking ability in adults with multiple sclerosis: a meta-analysis. Arch Phys Med Rehabil. 2015;96:1339–1348.
   PubMed Web of Science ®Google Scholar
• Motl RW, Pilutti LA. The benefits of exercise training in multiple sclerosis. Nat Rev Neurol. 2012;8:487–497.
   PubMed Web of Science ®Google Scholar
• Klaren RE, Motl RW, Woods JA, et al. Effects of exercise in experimental autoimmune encephalomyelitis (an animal model of multiple sclerosis). J Neuroimmunol. 2014;274:14–19.
   PubMed Web of Science ®Google Scholar
• Confavreux C, Vukusic S. Accumulation of irreversible disability in multiple sclerosis: from epidemiology to treatment. Clin Neurol Neurosurg. 2006;108:327–332.
   PubMed Web of Science ®Google Scholar
• Confavreux C, Vukusic S, Moreau T, et al. Relapses and progression of disability in multiple sclerosis. N Engl J Med. 2000;343:1430–1438.
   PubMed Web of Science ®Google Scholar
• Moher D, Hopewell S, Schulz KF, et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. J Clin Epidemiol. 2010;63:e1–37.
   PubMed Web of Science ®Google Scholar
• Mohr DC, Lovera J, Brown T, et al. A randomized trial of stress management for the prevention of new brain lesions in MS. Neurology. 2012;79:412–419.
   PubMed Web of Science ®Google Scholar
• Klaren RE, Hubbard EA, Motl RW, et al. Objectively measured physical activity is associated with brain volumetric measurements in multiple sclerosis. Behav Neurol. 2015;2015:482536.
   PubMed Web of Science ®Google Scholar
• Motl RW, Pilutti LA, Hubbard EA, et al. Cardiorespiratory fitness and its association with thalamic, hippocampal, and basal ganglia volumes in multiple sclerosis. NeuroImage Clin. 2015;7:661–666.
   PubMed Web of Science ®Google Scholar
• Pajonk F-G, Wobrock T, Gruber O, et al. Hippocampal plasticity in response to exercise in schizophrenia. Arch Gen Psychiatry. 2010;67:133–143.
   PubMed Web of Science ®Google Scholar
• Colcombe SJ, Erickson KI, Scalf PE, et al. Aerobic exercise training increases brain volume in aging humans. J Gerontol A Biol Sci Med Sci. 2006;61:1166–1170.
   PubMed Web of Science ®Google Scholar
• Colcombe SJ, Erickson KI, Raz N, et al. Aerobic fitness reduces brain tissue loss in aging humans. J Gerontol A Biol Sci Med Sci. 2003;58:176–180.
   PubMed Web of Science ®Google Scholar
• Colcombe SJ, Kramer AF, Erickson KI, et al. Cardiovascular fitness, cortical plasticity, and aging. Proc Natl Acad Sci U S A. 2004;101:3316–3321.
   PubMed Web of Science ®Google Scholar
• Erickson KI, Leckie RL, Weinstein AM. Physical activity, fitness, and gray matter volume. Neurobiol Aging. 2014;35:S20–28.
   PubMed Web of Science ®Google Scholar
• Erickson KI, Voss MW, Prakash RS, et al. Exercise training increases size of hippocampus and improves memory. Proc Natl Acad Sci U S A. 2011;108:3017–3022.
   PubMed Web of Science ®Google Scholar
• Ahlskog JE, Geda YE, Graff-Radford NR, et al. Physical exercise as a preventive or disease-modifying treatment of dementia and brain aging. Mayo Clin Proc. 2011;86:876–884.
   PubMed Web of Science ®Google Scholar
• Cotman CW, Berchtold NC. Exercise: a behavioral intervention to enhance brain health and plasticity. Trends Neurosci. 2002;25:295–301.
   PubMed Web of Science ®Google Scholar
• Szuhany KL, Bugatti M, Otto MW. A meta-analytic review of the effects of exercise on brain-derived neurotrophic factor. J Psychiatr Res. 2015;60:56–64.
   PubMed Web of Science ®Google Scholar
• Cotman CW, Berchtold NC, Christie L-A. Exercise builds brain health: key roles of growth factor cascades and inflammation. Trends Neurosci. 2007;30:464–472.
   PubMed Web of Science ®Google Scholar
• Motl RW, Sandroff BM, DeLuca J. Exercise training and cognitive rehabilitation: a symbiotic approach for rehabilitating walking and cognitive functions in multiple sclerosis? Neurorehabil Neural Repair. in press.
   Web of Science ®Google Scholar
• Marrie RA, Horwitz RI. Emerging effects of comorbidities on multiple sclerosis. Lancet Neurol. 2010;9:820–828.
   PubMed Web of Science ®Google Scholar
• Marrie RA, Rudick R, Horwitz R, et al. Vascular comorbidity is associated with more rapid disability progression in multiple sclerosis. Neurology. 2010;74:1041–1047.
   PubMed Web of Science ®Google Scholar
• Marrie RA, Elliott L, Marriott J, et al. Effect of comorbidity on mortality in multiple sclerosis. Neurology. 2015;85:240–247.
   PubMed Web of Science ®Google Scholar
• White LJ, Castellano V. Exercise and brain health-implications for multiple sclerosis: part 1 – neuronal growth factors. Sports Med. 2008;38:91–100.
   PubMed Web of Science ®Google Scholar
• White LJ, Castellano V. Exercise and brain health-implications for multiple sclerosis: part II – immune factors and stress hormones. Sports Med. 2008;38:179–186.
   PubMed Web of Science ®Google Scholar
• Kjølhede T, Vissing K, Dalgas U. Multiple sclerosis and progressive resistance training: a systematic review. Mult Scler. 2012;18:1215–1228.
   PubMed Web of Science ®Google Scholar
• Andreasen AK, Stenager E, Dalgas U. The effect of exercise therapy on fatigue in multiple sclerosis. Mult Scler. 2011;17:1041–1054.
   PubMed Web of Science ®Google Scholar
• Garrett M, Coote S. Multiple sclerosis and exercise in people with minimal gait impairment – a review. Phys Ther Rev. 2009;14:169–180.
   Google Scholar
• Rietberg MB, Brooks D, Uitdehaag BM, et al. Exercise therapy for multiple sclerosis. Cochrane Database Syst Rev. 2005;1:CD003980.
   PubMedGoogle Scholar
• Ensari I, Motl RW, Pilutti LA. Exercise training improves depressive symptoms in people with multiple sclerosis: results of a meta-analysis. J Psychosom Res. 2014;76:465–471.
   PubMed Web of Science ®Google Scholar
• Pilutti LA, Greenlee TA, Motl RW, et al. Effects of exercise training on fatigue in multiple sclerosis: a meta-analysis. Psychosom Med. 2013;75:575–580.
   PubMed Web of Science ®Google Scholar
• Paltamaa J, Sjögren T, Peurala SH, et al. Effects of physiotherapy interventions on balance in multiple sclerosis: a systematic review and meta-analysis of randomized controlled trials. J Rehabil Med. 2012;44:811–823.
   PubMed Web of Science ®Google Scholar
• Motl RW, Gosney JL. Effect of exercise training on quality of life in multiple sclerosis: a meta-analysis. Mult Scler. 2008;14:129–135.
   PubMed Web of Science ®Google Scholar